Literature DB >> 33597669

Comparative analysis of the alveolar microbiome in COPD, ECOPD, Sarcoidosis, and ILD patients to identify respiratory illnesses specific microbial signatures.

Shashank Gupta1,2, Malini Shariff3, Gaura Chaturvedi4,5, Agrima Sharma3, Nitin Goel6, Monika Yadav2, Martin S Mortensen1, Søren J Sørensen1, Mitali Mukerji4, Nar Singh Chauhan7.   

Abstract

Studying respiratory illness-specific microbial signatures and their interaction with other micro-residents could provide a better understanding of lung microbial ecology. Each respiratory illness has a specific disease etiology, however, so far no study has revealed disease-specific microbial markers. The present study was designed to determine disease-specific microbial features and their interactions with other residents in chronic obstructive pulmonary diseases (stable and exacerbated), sarcoidosis, and interstitial lung diseases. Broncho-alveolar lavage samples (n = 43) were analyzed by SSU rRNA gene sequencing to study the alveolar microbiome in these diseases. A predominance of Proteobacteria followed by Firmicutes, Bacteroidetes, Actinobacteria, and Fusobacteria was observed in all the disease subsets. Shannon diversity was significantly higher in stable COPD when compared to exacerbated chronic obstructive pulmonary disease (ECOPD) (p = 0.0061), and ILD patient samples (p = 0.037). The lung microbiome of the patients with stable COPD was more diverse in comparison to ECOPD and ILD patients (p < 0.001). Lefse analysis identified 40 disease-differentiating microbial features (LDA score (log10) > 4). Species network analysis indicated a significant correlation (p < 0.05) of diseases specific microbial signature with other lung microbiome members. The current study strengthens the proposed hypothesis that each respiratory illness has unique microbial signatures. These microbial signatures could be used as diagnostic markers to differentiate among various respiratory illnesses.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33597669      PMCID: PMC7889618          DOI: 10.1038/s41598-021-83524-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  47 in total

Review 1.  The role of the microbiome in exacerbations of chronic lung diseases.

Authors:  Robert P Dickson; Fernando J Martinez; Gary B Huffnagle
Journal:  Lancet       Date:  2014-08-23       Impact factor: 79.321

Review 2.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 3.  Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

4.  The cystic fibrosis lung microbiome.

Authors:  Michael G Surette
Journal:  Ann Am Thorac Soc       Date:  2014-01

5.  Atopobium and Fusobacterium as novel candidates for sarcoidosis-associated microbiota.

Authors:  Alexandra Zimmermann; Henrik Knecht; Robert Häsler; Gernot Zissel; Karoline I Gaede; Sylvia Hofmann; Almut Nebel; Joachim Müller-Quernheim; Stefan Schreiber; Annegret Fischer
Journal:  Eur Respir J       Date:  2017-12-14       Impact factor: 16.671

6.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Authors:  William D Travis; Ulrich Costabel; David M Hansell; Talmadge E King; David A Lynch; Andrew G Nicholson; Christopher J Ryerson; Jay H Ryu; Moisés Selman; Athol U Wells; Jurgen Behr; Demosthenes Bouros; Kevin K Brown; Thomas V Colby; Harold R Collard; Carlos Robalo Cordeiro; Vincent Cottin; Bruno Crestani; Marjolein Drent; Rosalind F Dudden; Jim Egan; Kevin Flaherty; Cory Hogaboam; Yoshikazu Inoue; Takeshi Johkoh; Dong Soon Kim; Masanori Kitaichi; James Loyd; Fernando J Martinez; Jeffrey Myers; Shandra Protzko; Ganesh Raghu; Luca Richeldi; Nicola Sverzellati; Jeffrey Swigris; Dominique Valeyre
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

7.  Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease.

Authors:  Philip L Molyneaux; Patrick Mallia; Michael J Cox; Joseph Footitt; Saffron A G Willis-Owen; Daniel Homola; Maria-Belen Trujillo-Torralbo; Sarah Elkin; Onn Min Kon; William O C Cookson; Miriam F Moffatt; Sebastian L Johnston
Journal:  Am J Respir Crit Care Med       Date:  2013-11-15       Impact factor: 21.405

8.  METAGENassist: a comprehensive web server for comparative metagenomics.

Authors:  David Arndt; Jianguo Xia; Yifeng Liu; You Zhou; An Chi Guo; Joseph A Cruz; Igor Sinelnikov; Karen Budwill; Camilla L Nesbø; David S Wishart
Journal:  Nucleic Acids Res       Date:  2012-05-29       Impact factor: 16.971

9.  Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa.

Authors:  L Millares; R Ferrari; M Gallego; M Garcia-Nuñez; V Pérez-Brocal; M Espasa; X Pomares; C Monton; A Moya; E Monsó
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-22       Impact factor: 3.267

10.  Functional metagenomics identifies novel genes ABCTPP, TMSRP1 and TLSRP1 among human gut enterotypes.

Authors:  Manoj Kumar Verma; Vasim Ahmed; Shashank Gupta; Jitendra Kumar; Rajesh Pandey; Vibha Mandhan; Nar Singh Chauhan
Journal:  Sci Rep       Date:  2018-01-23       Impact factor: 4.379

View more
  7 in total

1.  Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates.

Authors:  Matt S Zinter; A Birgitta Versluys; Caroline A Lindemans; Madeline Y Mayday; Gustavo Reyes; Sara Sunshine; Marilynn Chan; Elizabeth K Fiorino; Maria Cancio; Sabine Prevaes; Marina Sirota; Michael A Matthay; Sandhya Kharbanda; Christopher C Dvorak; Jaap J Boelens; Joseph L DeRisi
Journal:  Sci Transl Med       Date:  2022-03-09       Impact factor: 19.319

2.  The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis.

Authors:  Kristel S Knudsen; Sverre Lehmann; Rune Nielsen; Solveig Tangedal; Andreu Paytuvi-Gallart; Walter Sanseverino; Einar M H Martinsen; Pieter S Hiemstra; Tomas M Eagan
Journal:  Microbiome       Date:  2022-10-19       Impact factor: 16.837

Review 3.  The lung microbiome: progress and promise.

Authors:  Samantha A Whiteside; John E McGinniss; Ronald G Collman
Journal:  J Clin Invest       Date:  2021-08-02       Impact factor: 19.456

4.  Potential Association Between Changes in Microbiota Level and Lung Diseases: A Meta-Analysis.

Authors:  Lan Chai; Qi Wang; Caijuan Si; Wenyan Gao; Lun Zhang
Journal:  Front Med (Lausanne)       Date:  2022-01-14

5.  Pseudomonas aeruginosa modulates alginate biosynthesis and type VI secretion system in two critically ill COVID-19 patients.

Authors:  Jiuxin Qu; Zhao Cai; Lei Liu; Liang Yang; Xiangke Duan; Han Zhang; Hang Cheng; Shuhong Han; Kaiwei Yu; Zhaofang Jiang; Yingdan Zhang; Yang Liu; Fang Bai; Yingxia Liu
Journal:  Cell Biosci       Date:  2022-02-09       Impact factor: 7.133

Review 6.  Recent Advances in Understanding the Structure and Function of the Human Microbiome.

Authors:  Walaa K Mousa; Fadia Chehadeh; Shannon Husband
Journal:  Front Microbiol       Date:  2022-02-03       Impact factor: 5.640

7.  The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study.

Authors:  L Plantier; A Smolinska; R Fijten; M Flamant; J Dallinga; J J Mercadier; D Pachen; M P d'Ortho; F J van Schooten; B Crestani; A W Boots
Journal:  Respir Res       Date:  2022-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.